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Primary biliary cirrhosis (PBC) primarily affects females and is rarely complicated by 
hepatocellular carcinoma (HCC). Although HCC incidence in PBC patients is low, 
several characteristics and risk factors associated with its development have been 
reported. In this study, national data concerning the current status of carcinogenesis in 
PBC patients in Japan are reviewed. Using data from two national questionnaire surveys, 
we investigated the clinicopathological findings associated with HCC in PBC patients. 
According to the data of all reviewed PBC patients, HCC incidence was 2.4% (71/2946). 
HCC incidence by gender was 5.1% (19/370) in males and 2.0% (52/2576) in females, 
and the proportion of males was 26.7%. Prognosis was significantly poorer in the PBC 
patients with HCC than in those without. Multivariate analysis of risk factors associated 
with HCC by gender revealed histological stage at the time of PBC diagnosis as an 
independent risk factor associated with the development of HCC in females, but not in 
males. Furthermore, data from another national survey of 178 PBC patients with HCC 
(male/female = 49/129; proportion of males 27.5%) revealed that the duration between 
the diagnosis of PBC and that of HCC was significantly shorter in males than in females. 
In addition, histological stage at the time of HCC diagnosis was an independent risk 
factor for HCC in females, whereas no risk factors were identified in males. In 
conclusion, these data indicate that males are at risk of developing HCC at any 
histological stage of PBC. Therefore, male PBC patients in particular should be 
carefully screened for HCC from the early stages of PBC. 





































































Primary biliary cirrhosis (PBC) primarily affects middle-aged females. Histologically, the 
interlobular bile ducts are primarily damaged and show characteristic findings such as chronic 
nonsuppurative destructive cholangitis (CNSDC) followed by progressive bile duct loss.
1,2
 A terminal 
feature of PBC is irreversible biliary cirrhosis, and liver transplantation is the sole treatment for 
hepatic failure.
3
 Although hepatic failure defines the prognosis in most PBC patients, hepatocellular 
carcinoma (HCC) is also reported to occur in 0.76%–5.9% PBC patients.
4-9
 Recently, however, the 
incidence of PBC complicated by HCC has been gradually increasing with improvements in PBC 
treatment and survival. 
In general, HCC is typically encountered in the terminal stage, when irreversible biliary 
cirrhosis sets in. Moreover, the hepatitis virus is a major risk factor for HCC development in patients 
with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections. In PBC patients, 
however, no carcinogenic factors directly associated with HCC have been identified. The proposed 
risk factors for HCC arising from PBC-affected livers include the hepatitis virus, cirrhosis, older age, 
diabetic mellitus, and male gender.
4,5,10-13
 However, epidemiologic studies are limited and provide 
conflicting results, perhaps because of the low prevalence of the disease and geographical and 
environmental differences.  
In the present study, we evaluated data from two nationwide surveys performed in Japan. Our 
aim was to clarify the current status of carcinogenesis in PBC patients, identify the associated 








































































MATERIALS and METHODS 
 
Setting and patient selection 
A survey of PBC in Japan (national survey by the Intractable Hepato-Biliary Diseases Study 
Group) 
National surveys of PBC patients in Japan have been performed 14 times biennially or triennially by 
the Intractable Hepato-Biliary Diseases Study Group for Research on Measures for Intractable 
Disease, which is supported by Health Labour Sciences Research Grants in Japan. The subjects 
included 7376 patients registered in the 1st–14th surveys performed between 1980 and 2009.
9,14
 Of 
the 7376 patients, the absence or presence of HCC was confirmed during follow-up in 2946 (70 
males, 2576 females), who were then investigated in the current study. HBV carriers and HB 
antigen- and anti-HCV antibody-positive patients were excluded. 
A survey of PBC patients with HCC in Japan (national survey by the Liver Cancer Study Group of 
Japan) 
This project was set up at the 47th Annual Meeting of the Liver Cancer Study Group of Japan 
(President, Professor Ichida), and it was executed in 2011. Questionnaires were sent to 340 hospitals 
or institutions included in the Liver Cancer Study Group of Japan. Eighty-six of the 340 hospitals 
responded, and data from 178 PBC patients with HCC from 39 hospitals or institutions were 
eventually included. HBV carriers and HB antigen- and anti-HCV antibody-positive patients were 
excluded. The cooperating institutions are listed in the appendix.  
 
PBC diagnosis 
 PBC was diagnosed according to criteria established by the Intractable Hepato-Biliary 
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Diseases Study Group of Japan. Patients whose condition met one of the following criteria were 
diagnosed as having PBC: 1) histologically confirmed CNSDC with laboratory findings positive for 
PBC; 2) positivity for antimitochondrial (AMA) and/or anti-pyruvate dehydrogenase (PDH) 
antibodies, absence of histological findings of CNSDC, and presence of histological findings 
compatible with PBC; and 3) no histological examination, but positivity for AMA and/or anti-PDH 
dehydrogenase antibodies and clinical findings and course indicative of PBC. PBC symptoms were 
defined as pruritus, overt jaundice, esophageal varices, ascites, and hepatic encephalopathy.
15
 





 The Mann–Whitney U and chi-square tests test were used as nonparametric and 
independence tests, respectively. Logistic regression analysis was used for the multivariate analysis 
of prognostic factors. Survival rate was obtained by the Kaplan–Meier method. A p value of <0.05 




HCC incidence in the Japanese PBC population 
 The current status of and risk factors for HCC in PBC patients in Japan were analyzed on 
the basis of data from the national survey conducted by the Intractable Hepato-Biliary Diseases 
Study Group. The total number of PBC patients was 2946. Of these, 2100 cases available for 
analysis of histological stage of PBC at diagnosis underwent liver biopsy. HCC incidence during 
follow up was 2.4% (71/ 2946). This incidence was 5.1% (19/370) in males and 2.0% (52/2576) in 
females, and the proportion of males was 26.7%. The mean ± standard deviation and median values 
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for the observation period were 80.1 ± 70.8 (range, 1–443) and 58 months, respectively. The mean 
value for males was 65.1 ± 57.2 (range, 1–237; median, 45) months, while that for females was 82.2 
± 72.2 (range, 1–443; median, 60) months. 
 A comparative analysis of PBC patients with and without HCC revealed male gender, old 
age, low serum albumin levels, low serum total cholesterol levels, advanced histological stage, and 
symptomatic status at the time of PBC diagnosis as significant risk factors for HCC (Table 1). There 
was no difference in total bilirubin levels and the presence or absence of ursodeoxycholic acid 
(UDCA) treatment between the two groups (Table 1). Prognosis was significantly poorer in the PBC 
patients with HCC than in those without (Fig. 1). The cumulative incidence of carcinogenesis was 
6.5% in males and 2.0% in females during the 10 years after PBC diagnosis; the difference between 
males and females was statistically significant (p < 0.0001) (Fig. 2). In particular, analyses of HCC 
incidence in patients aged 10–80 years revealed that male PBC patients in their 40s and 50s had an 
increased risk of HCC compared with female PBC patients in the same age groups (data not shown). 
In multivariate analysis for risk factors of HCC, gender and histological stage were selected as 
significant factors (p < 0.00001) (Table 2). There was no difference in the proportion of males and 
females who underwent histological staging at PBC diagnosis. The incidence of histological stages 3 
and 4 was approximately 16.0% in both male and female PBC patients without HCC (Table 2), 
whereas that was 14.2% and 57.1% in male and female PBC patients with HCC, respectively. 
Advanced histological stage was a risk factor for HCC in females (p < 0.0001; Fig. 3 and Table 2). 
Multivariate analysis for risk factors of HCC by gender revealed that histological stage at the time of 
PBC diagnosis was an independent risk factor for HCC in females (supplementary Table 1), whereas 
no significant independent factors were revealed for males (supplementary Table 2). Moreover, 
although we assessed PBC patients with HCC according to histological stage, we found no 
difference in any clinical or biological characteristics between patients with and without cirrhosis at 
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PBC diagnosis (supplementary Table 3). 
 
PBC patients with HCC in Japan 
 From the data of the national survey specially set up at the 47th Annual Meeting of the 
Liver Cancer Study Group of Japan, we collected and investigated those for 178 PBC patients with 
HCC from a total of 39 hospitals included in the study group. These cases included 100 fatalities in 
the past years as well as 78 patients followed up from each hospital or institute as of June, 2011. 
Among the followed-up patients, four underwent liver transplantation, which was performed at the 
time of HCC discovery in three and 3 years after HCC discovery in one. There were 49 male and 
129 female PBC patients with HCC, and the proportion of males was 27.5%, which was similar to 
that from the previously described national survey of PBC. Although the average age at the time of 
for PBC diagnosis was slightly higher for males (68 years) than for females (62 years), that at the 
time of HCC diagnosis was similar between males (73 years) and females (72 years; Fig. 4). 
Moreover, the duration between the diagnosis of PBC and that of HCC was shorter in males than in 
females. HCC was diagnosed simultaneously with or prior to the diagnosis of PBC in 32.7% (16/49) 
males and 14.7% (19/129) females.  
 Pathological examination for HCC and background liver tissue assessment by biopsy or 
hepatectomy was conducted for 66 and 82 patients, respectively. Clinicopathological data at the time 
of HCC diagnosis are shown in Table 3. There were more males with prior HBV infection and a 
history of alcohol consumption compared with females. There were no differences in the history of 
blood transfusion, diabetes mellitus, AMA levels, anti-nuclear antibody levels, body mass index, 
serum triglyceride levels, serum total cholesterol levels associated with nonalcoholic fatty liver 
disease (including nonalcoholic steatohepatitis), and use of UDCA (Table 3) between males and 
females. However, an analysis excluding patients with past HBV infection and a history of alcohol 
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consumption revealed that there was no difference in other clinical findings, although the proportion 
of males (male/female = 24/104, 18.5%) remained higher than that of the total PBC male patients 
(male/female = 370/2576, 12.6%; p < 0.05; supplementary Table 4). Moreover, in females, HCC 
incidence gradually increased with histologic stage, while the incidence in males showed no trend or 
statistical significance. There was a significant difference in the distribution of histological stage 
between males and females (Fig. 5). An analysis of PBC patients with HCC according to histological 
stage revealed no clinical findings (including past HBV infection and alcohol consumption) that 
were significantly different between patients with and without cirrhosis at HCC diagnosis 
(supplementary Table 5). There was also no significant difference in tumor number and 




 Recently, we encountered PBC patients with HCC during routine pathological assessments, 
and the number of these patients appears to have increased according to reports from other 
institutes.
11,17,18
 In most patients, HCC is detected during follow-up for PBC, whereas some patients 
are simultaneously diagnosed with PBC and HCC or diagnosed with HCC prior to PBC. Although 
prognosis has improved with advances in treatment for PBC, the precise reason for the increased 
number of PBC patients with HCC in recent decades remains unknown. Therefore, we analyzed data 
from Japanese PBC patients and those with PBC and HCC who were independently surveyed by two 
different study groups. One set of data was from a national survey of PBC patients performed 14 
times between 1980 and 2009, while the other was from PBC patients with HCC who were 
evaluated as a special project of the Annual Meeting of the Liver Cancer Study Group of Japan in 
2011. Both surveys collected data through questionnaires administered to foundation hospitals or 
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specialized hospitals for hepatology in Japan. Therefore, although the investigative 
hospitals/institutions and objectives did not match, it is speculated that most PBC patients with HCC 
overlapped. Moreover, the proportion of males among PBC patients with HCC almost coincided in 
these two independent studies (26.7% vs 27.5%), validating the use of these studies together as 
representative of the situation in Japan. 
 Although some studies have reported that PBC patients do not have an increased risk of 
developing HCC,
19
 others showed that HCC incidence was high in PBC patients.
5,7,20
 HCC incidence 
among PBC patients is reportedly low at 0.76%–5.9% according to previous reports.
4-9
 In this study, 
we investigated the incidence of and risk factors for HCC in Japanese PBC patients. According to 
data from the nationwide survey by the Intractable Hepato-Biliary Diseases Study Group, HCC 
incidence was 2.4%. As for risk factors associated with HCC in PBC patients, several conflicting 
results have been reported.
4,5,11-13
 In general, male gender, advanced stage, HCV infection, and a 
history of blood transfusion were reported to be associated with HCC in PBC patients.
5,7,20
 In a 
proportional hazards analysis of patients with PBC in Japan, Shibuya et al.
5
 reported three factors to 
be independently associated with HCC development: age at the time of diagnosis, male gender, and 
history of blood transfusion. While autoimmune liver disease, including PBC, is more common in 
females than in males, HCC incidence in PBC patients was higher in males than in females. In 
agreement with previous reports from Japan, Europe, and USA,
4,5,11-13
 gender was identified as a risk 
factor associated with HCC in the nationwide survey of PBC patients conducted by the Intractable 
Hepato-Biliary Diseases Study Group. HCC incidence was 5.1% in males and 2.0% in females 
(proportion of males, 26.7%), indicating that male PBC patients had a 2.1-fold higher risk of HCC 
compared with female PBC patients. The proportion of males among the PBC patients with HCC 
was consistent with that in the nationwide survey by the Liver Cancer Study Group of Japan (27.5%). 
Moreover, cumulative HCC incidence was 6.5% in males and 2.0% in females during the 10 years 
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after PBC diagnosis, and male PBC patients had a 3.3-fold higher risk of HCC compared with 
females. In general, during the carcinogenesis of HCC, estrogen can protect hepatocytes from 
malignant transformation via downregulation of IL-6 release from Kupffer cells, indicating that 
estrogen-mediated inhibition of IL-6 production by Kupffer cells potentially decreased the risk of 
HCC in females.
21,22
 Therefore, although PBC primarily affects females, HCC may be more 
common in male PBC patients because of a lack of estrogen-mediated prevention. The national 
survey by the Liver Cancer Study Group of Japan revealed that the duration between the diagnosis of 
PBC and that of HCC was shorter in males than in females and that the diagnosis of HCC was 
performed simultaneously at or prior to the diagnosis of PBC in 32.7% males and 14.7% females. 
Several reasons may be responsible for the delayed diagnosis of PBC and carcinogenesis in the early 
stage in males, but the details remain unspecified. Moreover, the rate of past HBV infection and 
alcohol consumption was significantly higher in males than in females, indicating that these factors 
also possibly affect the increased HCC incidence in male PBC patients. Watanabe et al. reported that 
past HBV infection is an important factor in the association of HCC with PBC.
18
 In a patient with 
HBV infection, HBV-DNA possibly integrates into the human genome, but the frequency of this 
integration in prior HBV-infected PBC patients with HCC remains unknown. Moreover, because the 
distribution of past HBV infection by gender in the whole PBC population could not be obtained, the 
extent to which previous infection with HBV is directly associated with HCC carcinogenesis in male 
PBC patients remains debatable. However, analysis excluding cases with past HBV infection and a 
history of alcohol consumption revealed that the proportion of males with HCC in PBC patients with 
HCC remained high compared with that of all PBC male patients. In addition, analysis according to 
histological stage (non-cirrhosis vs. cirrhosis) suggested that past HBV infection and alcohol 
consumption were not directly associated with progression to cirrhosis in PBC patients with HCC. 
 In addition to male gender, the national survey by the Intractable Hepato-Biliary Diseases 
































































Harada et al.  - 11 - 
 
 
Study Group demonstrated that old age, low serum albumin levels, low total cholesterol levels, 
advanced histological stage, and symptomatic status at the time of PBC diagnosis were statistically 
significant in PBC patients with HCC compared to those without HCC. However, multivariate 
analysis by gender revealed that histological stage at the time of diagnosis of PBC was an 
independent risk factor for HCC in females, but not in males. In addition to at the time of diagnosis 
of PBC, at that of HCC, histological stage is associated with HCC by national survey for PBC with 
HCC patients. However, there was no difference in any clinical or biological characteristics between 
PBC patients with HCC with or without cirrhosis at HCC diagnosis. In females, HCC incidence 
gradually increased according to histological stage, indicating that the terminal stage of PBC, which 
is a cirrhotic state, may be a risk factor for HCC development in females, whereas males are likely to 
develop HCC at any stage. The carcinogenesis of HCC in PBC patients should be further clarified. 
PBC is pathologically characterized by CNSDC, and the main inflammatory lesions associated with 
PBC are not hepatocytes but cholangiocytes, which may be one of the reasons why HCC incidence 
in PBC patients is relatively low compared with the incidence of sustained hepatitic diseases such as 
chronic viral hepatitis and autoimmune hepatitis. Male PBC patients with HCC are thought to be a 
good model because they lack estrogen-mediated prevention of HCC. Unlike that in hepatitic 
diseases, intrahepatic cholestasis is found from the early stage in PBC,
1,23
 and some mitogenic 
factors in the bile of PBC patients presumably participate in the carcinogenesis of HCC from an 
early stage.
17,24
 However, this hypothesis remains a matter of speculation, and further study is 
required to clarify the molecular mechanism involved in the carcinogenesis of HCC in PBC patients.  
 In conclusion, we investigated the risk factors for HCC using data from two nationwide 
surveys of PBC patients in Japan. Because male PBC patients are at risk of developing HCC at any 
histologic stage, they should be carefully screened for HCC from an early stage of PBC, irrespective 
of histological stage. 
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Fig. 1  Kaplan–Meier curve for survival in patients with primary biliary cirrhosis with (+) or 
without (−) hepatocellular carcinoma. There is a statistically significant difference between 
the curves (p < 0.05).  
 
Fig. 2 Cumulative appearance rates of hepatocellular carcinomsa in patients with primary biliary 
cirrhosis by gender. There is a statistically significant difference between males and females.  
 
Fig. 3 Histological stage at the diagnosis of primary biliary cirrhosis (PBC) in patients with or 
without hepatocellular carcinoma (HCC) by gender. The proportion of patients with 
histological stages 3 and 4 at the time of PBC diagnosis is approximately 16.0% for both 
male and female PBC patients without HCC. However, the proportion of patients with 
histological stages 3 and 4 is 14.2% in male and 57.1% in female PBC patients with HCC. 
Moreover, there is a significant difference in the proportion of female PBC patients with 
HCC and that without. The parentheses identify the number of patients examined. 
 
Fig. 4 Average age at the time of diagnosis of primary biliary cirrhosis (PBC) and hepatocellular 
carcinoma (HCC), and the duration between the diagnosis of PBC and that of HCC. The 
duration between the diagnosis of PBC and that of HCC is shorter in males than in females 
(p < 0.05). The parentheses identify the number of patients examined. 
 
Fig. 5 Histologic stage by gender at the time of hepatocellular carcinoma (HCC) diagnosis in 
patients with primary biliary cirrhosis. In females, HCC incidence gradually increases 
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according to histological stage, with a statistically significant difference (p < 0.05). The 
parentheses indicate the number of patients examined. 
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